Next, we examined the molecular and cellular biomarkers associated with reduced tumor volumes seen in the anti-VSIG4 and anti-PD-1 treatment groups, by analyzing tumor tissues and blood serum collected mid-study (17 days after the first dose by which time the tumor sizes were not dramatically different between the treatment groups). The gene discussed is VSIG4; the disease is neoplasm.